Literature DB >> 17803225

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.

Göran Bertilsson1, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm, Lilian Wikström.   

Abstract

We investigated the effects of exendin-4 on neural stem/progenitor cells in the subventricular zone of the adult rodent brain and its functional effects in an animal model of Parkinson's disease. Our results showed expression of GLP-1 receptor mRNA or protein in the subventricular zone and cultured neural stem/progenitor cells isolated from this region. In vitro, exendin-4 increased the number of neural stem/progenitor cells, and the number of cells expressing the neuronal markers microtubule-associated protein 2, beta-III-tubulin, and neuron-specific enolase. When exendin-4 was given intraperitoneally to naïve rodents together with bromodeoxyuridine, a marker for DNA synthesis, both the number of bromodeoxyuridine-positive cells and the number of neuronal precursor cells expressing doublecortin were increased. Exendin-4 was tested in the 6-hydroxydopamine model of Parkinson's disease to investigate its possible functional effects in an animal model with neuronal loss. After unilateral lesion and a 5-week stabilization period, the rats were treated for 3 weeks with exendin-4. We found a reduction of amphetamine-induced rotations in animals receiving exendin-4 that persisted for several weeks after drug administration had been terminated. Histological analysis showed that exendin-4 significantly increased the number of both tyrosine hydroxylase- and vesicular monoamine transporter 2-positive neurons in the substantia nigra. In conclusion, our results show that exendin-4 is able to promote adult neurogenesis in vitro and in vivo, normalize dopamine imbalance, and increase the number of cells positive for markers of dopaminergic neurons in the substantia nigra in a model of Parkinson's disease. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17803225     DOI: 10.1002/jnr.21483

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  118 in total

1.  GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.

Authors:  C G Jolivalt; M Fineman; C F Deacon; R D Carr; N A Calcutt
Journal:  Diabetes Obes Metab       Date:  2011-11       Impact factor: 6.577

2.  Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.

Authors:  Yazhou Li; David Tweedie; Mark P Mattson; Harold W Holloway; Nigel H Greig
Journal:  J Neurochem       Date:  2010-04-02       Impact factor: 5.372

3.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 4.  Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke.

Authors:  Vladimer Darsalia; Martin Larsson; David Nathanson; Thomas Klein; Thomas Nyström; Cesare Patrone
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-11       Impact factor: 6.200

5.  The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders.

Authors:  Rodrigo B Mansur; Gabriel R Fries; Alisson P Trevizol; Mehala Subramaniapillai; Julie Lovshin; Kangguang Lin; Maj Vinberg; Roger C Ho; Elisa Brietzke; Roger S McIntyre
Journal:  Eur Neuropsychopharmacol       Date:  2018-11-06       Impact factor: 4.600

6.  Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.

Authors:  Miaad Bader; Yazhou Li; Daniela Lecca; Vardit Rubovitch; David Tweedie; Elliot Glotfelty; Lital Rachmany; Hee Kyung Kim; Ho-Il Choi; Barry J Hoffer; Chaim G Pick; Nigel H Greig; Dong Seok Kim
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

Review 7.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

8.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

9.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

10.  The impact of dietary energy intake on cognitive aging.

Authors:  Mark P Mattson
Journal:  Front Aging Neurosci       Date:  2010-03-08       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.